Operates as a chronic disease hospital

MipSalus ApS is a Danish private company located in Hørsholm. The firm engages in research and experimental development on natural sciences and engineering.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. OT-58, their lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

Labsystems Diagnostics Oy is a diagnostic research and development firm that specializes in newborn screening and point-of-care testing technology. Labsystems specializes in enzyme immunoassays (EIA and FEIA) as well as fast point-of-care diagnostics for professionals and consumers. Labsystems Diagnostics Oy is a Finnish company that designs and manufactures full newborn screening systems, as well as infectious disease and gastrointestinal diagnostics.

Rubius Therapeutics is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures.

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Waltham, MA.

Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

Meiji Co., Ltd. produces and sells milk, dairy, confectioneries, and food. Its products include cheese, ice cream, chocolate, infant formula, whey protein, beauty supplements, and yogurt. The company was founded on December 21, 1917 and is headquartered in Tokyo, Japan.

National Center of Neurology and Psychiatry provides treatment and prevention therapy for mental, nervous, and developmental disorders.

Shenzhen Weihang Yining Biotechnology Co., Ltd., established on 2022-02-22, Business scope includes general business items:Biotechnology Extension Services;R&D and application of cell technology;Engineering and Technology Research and Experimental Development;Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Natural science research and experimental development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Manufactures chemicals

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”